Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors

Mortensen, Svend Aage; Leth, A; Agner, E; Rohde, Morten

doi:10.1016/s0098-2997(97)00014-9

Cited by 182 publications

(88 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However it is not uncommon that statin treated patients experience side effects like myalgia or even myopathy. That the serum level of coenzyme Q10 is decreased during statin treatment is well documented [64].…”

Section: Selenium and Coenzyme Q10 In Statin Treatmentmentioning

confidence: 98%

Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician's point of view

Alehagen

Aaseth

2015

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

show abstract

Section: Selenium and Coenzyme Q10 In Statin Treatmentmentioning

confidence: 98%

Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician's point of view

Alehagen

Aaseth

2015

Journal of Trace Elements in Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…1 By inhibiting hydroxyl-methyl-glutaryl Co-A reductase, which is involved in the synthesis of a substrate for cholesterol and Co-enzyme Q10, statins ultimately decrease levels of cholesterol and co-enzyme Q10. 2,3 Two studies reporting an association between low cholesterol and PD suggest that low cholesterol or low Co-enyzme Q10 increase the risk of Parkinson's disease (PD) thus raising the possibility that statin use might be harmful to the dopaminnergic system. 4,5 On the other hand there is considerable biological evidence suggesting that statins have neuroprotective properties.…”

Section: Introductionmentioning

confidence: 99%

Statin use and the risk of Parkinson disease

Wahner

Bronstein²,

Bordelon³

et al. 2008

Neurology

120

115

View full text Add to dashboard Cite

Objective-To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson's disease (PD)Methods-We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties. Controls were marginally matched to cases by age, race, and gender.Results-We observed a higher frequency of statin use among controls versus cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (≥5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60-70% risk reductions for each individual statin except pravastatin.Conclusion-Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD. Terms

show abstract

“…Secondary outcomes will assess impact of treatment on other factors that could influence an effect-favorable or adverse-of treatment on behavior and cognition, such as GABA, corticosteroids, or testosterone, blood pressure, insulin/glucose, and other parameters. Blood will be archived for possible future testing, e.g., of coenzyme Q10, for correlation with noncardiac adverse outcomes, if any [113,114].…”

mentioning

confidence: 99%

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes

Golomb

Criqui

White

et al. 2004

Controlled Clinical Trials

View full text Add to dashboard Cite

There has been persistent controversy regarding possible favorable or adverse effects of statins or of cholesterol reduction on cognition, mood and behavior (including aggressive or violent behavior), muscle function, and quality of life. The UCSD Statin Study seeks to ascertain the beneficial or adverse effects of statin cholesterol-lowering drugs on a set of noncardiac endpoints, including cognition, behavior, and serotonin biochemistry. The study will enroll 1000 subjects (minimum 20% female) of mixed ethnicity from San Diego. Subjects must be age 20 and older, postmenopausal if female, without known cardiovascular disease or diabetes, and with LDLcholesterol between 115 and 190 mg/dl. Subjects will be randomized to a double-blind, placebocontrolled trial with assignment 1/3, 1/3, 1/3 to placebo, simvastatin 20 mg, or pravastatin 40 mg (equipotent LDL-cholesterol-lowering doses for drug arms with simvastatin and pravastatin chosen to represent the extremes of the lipophilicity spectrum) for 6 months of treatment followed by 2 months postcessation follow-up. Primary outcomes are cognition (cognitive battery), irritability/aggression (behavior measure), and serotonin (gauged by whole blood serotonin), assessed as the difference between baseline and 6 months, judging combined statin groups vs. placebo. Secondary outcomes include mood (CES-D and Wakefield depression inventory), quality of life (SF-12V), sleep (Leeds sleep scale, modified), and secondary aggression measures (Conflict Tactics Scale; Overt Aggression Scale, Modified). Cardiovascular reactivity will be examined in a 10% subset. As additional secondary endpoints, primary and selected secondary outcomes will be assessed by statin assignment (lipophilic simvastatin vs. hydrophilic pravastatin). "Reversibility" of changes, if any, at 2 months postcessation will be determined. If effects (favorable or unfavorable) are identified, we will seek to ascertain whether there are baseline variables that predict who will be most susceptible to these favorable or adverse noncardiac effects (i.e., effect modification). NIH Public Access BackgroundStatins are important and widely prescribed drugs, with well-documented and incontrovertible cardiac benefits. However, controversy remains regarding the existence and impact of noncardiac effects, including central nervous system (CNS) effects. The University of California-San Diego (UCSD) Statin Study, a National Institutes of Health/ National Heart Lung and Blood Institute-funded double-blind, placebo-controlled study, seeks to address these issues through a complex battery of tests assessing noncardiac outcomes pertaining to cognition, behavior, quality of life, and biochemistry, among other endpoints. This paper provides the general methodology employed and addresses certain theoretical issues in study design.Statin cholesterol-lowering drugs (HMG-CoA reductase inhibitors) are the most prescribed drugs in the United States and the world and contributed substantially to prescription drug cost increases in 200...

show abstract

Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors

Cited by 182 publications

References 12 publications

Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician's point of view

Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician's point of view

Statin use and the risk of Parkinson disease

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes

Contact Info

Product

Resources

About